Valuation : Tyra Biosciences, Inc.

Market Cap 1.4B 1.21B 1.15B 1.04B 1.95B 134B 1.96B 13.61B 5.23B 68.28B 5.28B 5.16B 216B P/E 2026 *
-8.77x
P/E 2027 * -8.15x
Enterprise Value 914M 788M 746M 676M 1.27B 87.34B 1.27B 8.86B 3.41B 44.43B 3.43B 3.36B 140B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Tyra Biosciences, Inc.

1 day-2.72%
1 week-19.55%
Current month-7.91%
1 month-8.46%
3 months-9.86%
6 months-36.92%
Current year-12.32%
1 week 18.66
Extreme 18.66
29.49
1 month 18.66
Extreme 18.66
29.56
Current year 18.66
Extreme 18.66
40.65
1 year 11.82
Extreme 11.82
40.65
3 years 6.42
Extreme 6.42
40.65
5 years 4.93
Extreme 4.93
40.65
10 years 4.93
Extreme 4.93
40.65
Manager TitleAgeSince
Chief Operating Officer 51 01/11/2018
Chief Executive Officer 46 01/11/2018
Director of Finance/CFO 69 01/01/2023
Director TitleAgeSince
Chairman 58 01/03/2019
Director/Board Member 46 02/08/2018
Director/Board Member 40 01/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
5/28/26 A Free

Director

13,160 0.0221%
5/28/26 A Free

Director

13,160 0.0221%
5/28/26 A Free

Director

13,160 0.0221%
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%-19.55%+84.84%+53.87% 1.4B
-2.11%-3.44%+41.04%+98.48% 68.24B
-0.23%-4.45%+30.39%+73.64% 62.23B
+0.15%+0.59%-12.86%+379.40% 27.8B
-1.05%-7.30%+25.00%+12.31% 24.86B
+0.71%-6.45%-6.94%-17.70% 24.22B
+0.43%-3.37%+14.85%-19.29% 19.36B
-3.03%-5.19%+192.88%+340.13% 17.28B
-1.94%-6.36%-7.05%+516.16% 14.46B
-2.23%-5.04%+43.42%+154.82% 14.23B
Average -1.20%-4.09%+40.56%+159.18% 27.41B
Weighted average by Cap. -0.99%-3.81%+33.00%+134.90%

Financials

2026 *2027 *
Net sales - -
Net income -178M -153M -145M -131M -246M -16.97B -248M -1.72B -662M -8.64B -667M -653M -27.29B -211M -182M -172M -156M -293M -20.19B -295M -2.05B -787M -10.27B -794M -776M -32.46B
Net Debt -491M -423M -400M -363M -681M -46.87B -684M -4.75B -1.83B -23.85B -1.84B -1.8B -75.35B -323M -278M -263M -239M -448M -30.85B -450M -3.13B -1.2B -15.69B -1.21B -1.19B -49.59B
Logo Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).
Employees
87
Date Price Change Volume
11/09/26 $23.11 -1.83% 524,328
10/09/26 $23.54 +6.95% 2,477,607
09/09/26 $22.01 -17.66% 6,069,061
08/09/26 $26.73 -6.70% 1,158,785
04/09/26 $28.65 +15.25% 1,864,601
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
23.54USD
Average target price
48.80USD
Spread / Average Target
+107.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TYRA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!